For some perspective on how undervalued RAC would seem to be at this point, Imugene added $170 million of market capitalisation today (at closing price, intra-day it was up $230 million) - now $1.17 billion total market cap. They released an announcement regarding dosing the first patient in a phase 1 trial that will run for 2 years (there was no mention of early readouts, but I guess it's possible).
RACs total market capitalisation is currently about $270 million.
RAC - Charts & Price Action, page-11964
-
- There are more pages in this discussion • 9,769 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
